Biliary excretion of aztreonam in patients with biliary tract disease.

Antimicrobial Agents and Chemotherapy
O V MartinezR G Devlin

Abstract

The biliary excretion of aztreonam was studied in 10 post-cholecystectomy patients with T-tube biliary drainage (group A) and four other subjects with obstructive biliary tract disease who had recent placement of external biliary drainage (group B). Maximum biliary levels ranged from 9.7 to 88.2 micrograms/ml (mean, 42.9 +/- 7.9 micrograms/ml) and occurred 2.4 h after injection of a single 1-g dose intravenously. Peak biliary levels observed in group B patients were approximately one-third those in group A. Cumulative 12-h biliary excretion (group B) accounted for 0.18 +/- 0.06% of the total dose. In the same period, urinary excretion accounted for 65 to 72% of the total dose. The lower biliary levels of aztreonam observed in group B patients relative to those in group A suggest that in patients with total biliary tract obstruction the liver may not recover full secretory capacity, at least within 3 to 7 days after biliary decompression.

References

Jun 1, 1978·Antimicrobial Agents and Chemotherapy·K R RatzanI Lauredo
Jun 1, 1976·The Journal of Antimicrobial Chemotherapy·M PingetJ Lavillaureix
Jan 1, 1973·Antimicrobial Agents and Chemotherapy·J M BrogardJ Lavillaureix
Feb 1, 1981·Antimicrobial Agents and Chemotherapy·J A GironS Z Hirschman
Mar 1, 1983·Infection·F KeesL Safrany
Aug 1, 1981·Antimicrobial Agents and Chemotherapy·O V MartinezN Einhorn
Sep 1, 1983·Antimicrobial Agents and Chemotherapy·E A SwabbA Sugerman
Dec 1, 1981·The Journal of Antimicrobial Chemotherapy·E A SwabbA A Sugerman

❮ Previous
Next ❯

Citations

Apr 23, 1993·Pharmacy World & Science : PWS·P CherrierF Fauvelle
Jan 26, 2007·Journal of Hepato-biliary-pancreatic Surgery·Atsushi TanakaKui-Hin Liau
Jan 26, 2007·Journal of Hepato-biliary-pancreatic Surgery·Masahiro YoshidaChen-Guo Ker
Jan 6, 2011·Current Gastroenterology Reports·Patrick Mosler
Oct 1, 1984·Antimicrobial Agents and Chemotherapy·C M MacLeodR G Devlin
Dec 1, 1985·Antimicrobial Agents and Chemotherapy·J I BlenkharnI S Benjamin
Jun 1, 1986·Antimicrobial Agents and Chemotherapy·R E CondonB Levinson
Sep 1, 1986·Antimicrobial Agents and Chemotherapy·T R BeamM A Leitz
Apr 30, 1999·Mayo Clinic Proceedings·W C Hellinger, N S Brewer
Jun 24, 2016·The Journal of Antimicrobial Chemotherapy·Christopher Ramsey, Alasdair P MacGowan
Jul 1, 1986·Pharmacotherapy·S J Childs, G P Bodey
Nov 1, 1996·Antimicrobial Agents and Chemotherapy·S J van den HazelD J van Leeuwen

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.